FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012113293> ?p ?o ?g. }

• W2012113293 endingPage "2" @default.
• W2012113293 startingPage "1" @default.
• W2012113293 abstract "CNS OncologyVol. 1, No. 1 ForewordFree AccessCNS Oncology: reflecting a rapidly changing landscapeHenry S Friedman & Alba A BrandesHenry S Friedman* Author for correspondenceDuke University Medical Center, 047 Baker House, Trent Drive, DUMC Box 3624, Durham, NC 27710, USA. Search for more papers by this authorEmail the corresponding author at henry.friedman@duke.edu & Alba A BrandesAzienda USL of Bologna, Department of Medical Oncology, Azienda USL of Bologna, Via Altura 3, Bologna, 40139, ItalySearch for more papers by this authorPublished Online:31 Aug 2012https://doi.org/10.2217/cns.12.7AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail We are delighted, as the Senior Editors of the new journal CNS Oncology, to introduce ourselves and welcome you to our seminal issue. We hope that you will find the content relevant to our field and be eager to both read the first issue as well as submit to future issues. The contributions of Victoria Lane, the Launch Editor for Future Medicine, Ltd, the administrator of CNS Oncology, cannot be overstated. We are grateful for the opportunity to work with her in the production of this journal.CNS Oncology will contain articles that reflect the rapidly changing landscape in the field of neuro-oncology. We hope to focus on the major issues of both primary and metastatic brain tumors in a timely fashion and generate meaningful dialogue regarding a broad spectrum of issues important to clinical and laboratory investigation of these tumors.It is now impossible to attend a neuro-oncology meeting without passionate discussions on a broad spectrum of issues. These include, but are by no means limited to, the optimal therapy of primary and metastatic brain tumors, the appropriate role of imaging modalities in detecting both progression and response to therapy of these tumors, the role that genomic analysis plays in altering therapeutic strategies, the potential for personalized medicine using a platform of complete tumor genomic analyses, the particular issues that may arise with newer modalities such as antiangiogenic therapy, the role of newer interventions such as immunotherapy and, because we fortunately have an increasing population of survivors, the appropriate way to be sure that long-term survivors receive rigorous attention to the consequences of their tumor and the therapy chosen to treat it.We recognize that consensus is never possible in neuro-oncology and hope that a vigorous dialogue generated by the articles chosen for publication in CNS Oncology will lead to intellectual debates that can result in improvements in the treatment and outcome of patients with brain tumors. We welcome submissions on all topics of neuro-oncology and are particularly interested in publishing articles that will have opposing views, allowing the generation of meaningful discussions. In other words, controversial topics are particularly welcome as they frequently lead to the most important discussions in any given field.As you will see, there are subjects that are in both this inaugural issue and future issues of CNS Oncology that will reflect the many issues detailed above and, we hope, lead to our field moving forward. There is no question that much work needs to be done in neuro-oncology, and CNS Oncology hopes to play a major role in disseminating this information to a broad constellation of physicians and scientists involved in the neuro-oncology field.Financial & competing interests disclosureH Friedman is a speaker, advisor and consultant for Genentech, Inc. (Roche Holding), a consultant and speaker for Eisai, Inc. and owns equity in Arno Therapeutics, Inc. He is also a consultant for Tactical Therapeutics and MedTrust. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.FiguresReferencesRelatedDetails Vol. 1, No. 1 Follow us on social media for the latest updates Metrics Downloaded 380 times History Published online 31 August 2012 Published in print September 2012 Information© Future Medicine LtdFinancial & competing interests disclosureH Friedman is a speaker, advisor and consultant for Genentech, Inc. (Roche Holding), a consultant and speaker for Eisai, Inc. and owns equity in Arno Therapeutics, Inc. He is also a consultant for Tactical Therapeutics and MedTrust. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2012113293 created "2016-06-24" @default.
• W2012113293 creator A5057371623 @default.
• W2012113293 creator A5087336206 @default.
• W2012113293 date "2012-09-01" @default.
• W2012113293 modified "2023-10-15" @default.
• W2012113293 title "CNS Oncology: reflecting a rapidly changing landscape" @default.
• W2012113293 doi "https://doi.org/10.2217/cns.12.7" @default.
• W2012113293 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6176826" @default.
• W2012113293 hasPublicationYear "2012" @default.
• W2012113293 type Work @default.
• W2012113293 sameAs 2012113293 @default.
• W2012113293 citedByCount "0" @default.
• W2012113293 crossrefType "journal-article" @default.
• W2012113293 hasAuthorship W2012113293A5057371623 @default.
• W2012113293 hasAuthorship W2012113293A5087336206 @default.
• W2012113293 hasBestOaLocation W20121132932 @default.
• W2012113293 hasConcept C121608353 @default.
• W2012113293 hasConcept C126322002 @default.
• W2012113293 hasConcept C143998085 @default.
• W2012113293 hasConcept C15744967 @default.
• W2012113293 hasConcept C2776598537 @default.
• W2012113293 hasConcept C71924100 @default.
• W2012113293 hasConceptScore W2012113293C121608353 @default.
• W2012113293 hasConceptScore W2012113293C126322002 @default.
• W2012113293 hasConceptScore W2012113293C143998085 @default.
• W2012113293 hasConceptScore W2012113293C15744967 @default.
• W2012113293 hasConceptScore W2012113293C2776598537 @default.
• W2012113293 hasConceptScore W2012113293C71924100 @default.
• W2012113293 hasIssue "1" @default.
• W2012113293 hasLocation W20121132931 @default.
• W2012113293 hasLocation W20121132932 @default.
• W2012113293 hasLocation W20121132933 @default.
• W2012113293 hasOpenAccess W2012113293 @default.
• W2012113293 hasPrimaryLocation W20121132931 @default.
• W2012113293 hasRelatedWork W1992755712 @default.
• W2012113293 hasRelatedWork W2197671940 @default.
• W2012113293 hasRelatedWork W2257973466 @default.
• W2012113293 hasRelatedWork W2385020530 @default.
• W2012113293 hasRelatedWork W2618018078 @default.
• W2012113293 hasRelatedWork W2748952813 @default.
• W2012113293 hasRelatedWork W2899084033 @default.
• W2012113293 hasRelatedWork W4206824904 @default.
• W2012113293 hasRelatedWork W4234632001 @default.
• W2012113293 hasRelatedWork W4299900860 @default.
• W2012113293 hasVolume "1" @default.
• W2012113293 isParatext "false" @default.
• W2012113293 isRetracted "false" @default.
• W2012113293 magId "2012113293" @default.
• W2012113293 workType "article" @default.